These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
363 related articles for article (PubMed ID: 28617621)
1. The ESMO-Magnitude of Clinical Benefit Scale for novel oncology drugs: correspondence with three years of reimbursement decisions in Israel. Hammerman A; Greenberg-Dotan S; Feldhamer I; Birnbaum Y; Cherny NI Expert Rev Pharmacoecon Outcomes Res; 2018 Feb; 18(1):119-122. PubMed ID: 28617621 [TBL] [Abstract][Full Text] [Related]
2. Five years of EMA-approved systemic cancer therapies for solid tumours-a comparison of two thresholds for meaningful clinical benefit. Grössmann N; Del Paggio JC; Wolf S; Sullivan R; Booth CM; Rosian K; Emprechtinger R; Wild C Eur J Cancer; 2017 Sep; 82():66-71. PubMed ID: 28648700 [TBL] [Abstract][Full Text] [Related]
3. Time to access to novel anticancer drugs and the correlation with ESMO-Magnitude of Clinical Benefit Scale in Slovenia. Janzic U; Knez L; Janzic A; Cufer T Expert Rev Pharmacoecon Outcomes Res; 2019 Dec; 19(6):717-723. PubMed ID: 31826655 [No Abstract] [Full Text] [Related]
4. Twelve years of European cancer drug approval-a systematic investigation of the 'magnitude of clinical benefit'. Grössmann N; Wolf S; Rothschedl E; Wild C ESMO Open; 2021 Jun; 6(3):100166. PubMed ID: 34087744 [TBL] [Abstract][Full Text] [Related]
5. [Evaluation of Anti-cancer Therapies with Reimbursement Limited to Comprehensive Cancer Centres Using the European Society for Medical Oncology Magnitude of Clinical Benefit Scale]. Büchler T; Melichar B; Vrána D; Lemstrová R; Fínek J; Dušek L; Petráková K; Prausová J Klin Onkol; 2017; 30(5):349-360. PubMed ID: 29031037 [TBL] [Abstract][Full Text] [Related]
6. Examining the association between oncology drug clinical benefit and the time to public reimbursement. Thomson S; Everest L; Witzke N; Jiao T; Delos Santos S; Nguyen V; Cheung MC; Chan KKW Cancer Med; 2022 Jan; 11(2):380-391. PubMed ID: 34850587 [TBL] [Abstract][Full Text] [Related]
7. Assessing the benefit of cancer drugs approved by the European Medicines Agency using the European Society for Medical Oncology Magnitude of Clinical Benefit Scale over time. Thomson S; Witzke N; Gyawali B; Delos Santos S; Udayakumar S; Cardone C; Cheung MC; Chan KKW Eur J Cancer; 2021 Jun; 150():203-210. PubMed ID: 33932727 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of changes in the clinical benefits of oncology drugs over time following reimbursement using the ASCO-VF and the ESMO-MCBS. Yoon NR; Na YJ; Lee JH; Song I; Lee EK; Park MH J Cancer Res Clin Oncol; 2024 Mar; 150(3):113. PubMed ID: 38436796 [TBL] [Abstract][Full Text] [Related]
9. Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration. Tibau A; Molto C; Ocana A; Templeton AJ; Del Carpio LP; Del Paggio JC; Barnadas A; Booth CM; Amir E J Natl Cancer Inst; 2018 May; 110(5):486-492. PubMed ID: 29244173 [TBL] [Abstract][Full Text] [Related]
10. Clinical benefit of cancer drugs approved in Switzerland 2010-2019. Adam R; Tibau A; Molto Valiente C; Šeruga B; Ocaña A; Amir E; Templeton AJ PLoS One; 2022; 17(6):e0268545. PubMed ID: 35687539 [TBL] [Abstract][Full Text] [Related]
11. ESMO-Magnitude of Clinical Benefit Scale for haematological malignancies (ESMO-MCBS:H) version 1.0. Kiesewetter B; Dafni U; de Vries EGE; Barriuso J; Curigliano G; González-Calle V; Galotti M; Gyawali B; Huntly BJP; Jäger U; Latino NJ; Malcovati L; Oosting SF; Ossenkoppele G; Piccart M; Raderer M; Scarfò L; Trapani D; Zielinski CC; Wester R; Zygoura P; Macintyre E; Cherny NI; Ann Oncol; 2023 Sep; 34(9):734-771. PubMed ID: 37343663 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of the Clinical Benefit of Cancer Drugs Submitted for Reimbursement Recommendation Decisions in Canada. Meyers DE; Jenei K; Chisamore TM; Gyawali B JAMA Intern Med; 2021 Apr; 181(4):499-508. PubMed ID: 33616606 [TBL] [Abstract][Full Text] [Related]
13. Clinical benefit and cost of breakthrough cancer drugs approved by the US Food and Drug Administration. Molto C; Hwang TJ; Borrell M; Andres M; Gich I; Barnadas A; Amir E; Kesselheim AS; Tibau A Cancer; 2020 Oct; 126(19):4390-4399. PubMed ID: 32697362 [TBL] [Abstract][Full Text] [Related]
14. Prices and clinical benefit of cancer drugs in the USA and Europe: a cost-benefit analysis. Vokinger KN; Hwang TJ; Grischott T; Reichert S; Tibau A; Rosemann T; Kesselheim AS Lancet Oncol; 2020 May; 21(5):664-670. PubMed ID: 32359489 [TBL] [Abstract][Full Text] [Related]
15. Comparison of Long-term Survival Benefits in Trials of Immune Checkpoint Inhibitor vs Non-Immune Checkpoint Inhibitor Anticancer Agents Using ASCO Value Framework and ESMO Magnitude of Clinical Benefit Scale. Everest L; Shah M; Chan KKW JAMA Netw Open; 2019 Jul; 2(7):e196803. PubMed ID: 31290990 [TBL] [Abstract][Full Text] [Related]
16. Application of the ESMO Magnitude of Clinical Benefit Scale to assess the clinical benefit of antibody drug conjugates in solid cancer: a systematic descriptive analysis of phase III and pivotal phase II trials. Ding L; Yuan X; Wang Y; Shen Z; Wu P BMJ Open; 2024 Jun; 14(6):e077108. PubMed ID: 38851227 [TBL] [Abstract][Full Text] [Related]
17. Do the American Society of Clinical Oncology Value Framework and the European Society of Medical Oncology Magnitude of Clinical Benefit Scale Measure the Same Construct of Clinical Benefit? Cheng S; McDonald EJ; Cheung MC; Arciero VS; Qureshi M; Jiang D; Ezeife D; Sabharwal M; Chambers A; Han D; Leighl N; Sabarre KA; Chan KKW J Clin Oncol; 2017 Aug; 35(24):2764-2771. PubMed ID: 28574778 [TBL] [Abstract][Full Text] [Related]
18. Access to novel cancer medicines in four countries in Central and Eastern Europe in relation to clinical benefit. Hofmarcher T; Szilagyiova P; Gustafsson A; Dolezal T; Rutkowski P; Baxter C; Karamousouli E ESMO Open; 2023 Aug; 8(4):101593. PubMed ID: 37413761 [TBL] [Abstract][Full Text] [Related]
19. Comparative Assessment of Clinical Benefit Using the ESMO-Magnitude of Clinical Benefit Scale Version 1.1 and the ASCO Value Framework Net Health Benefit Score. Cherny NI; de Vries EGE; Dafni U; Garrett-Mayer E; McKernin SE; Piccart M; Latino NJ; Douillard JY; Schnipper LE; Somerfield MR; Bogaerts J; Karlis D; Zygoura P; Vervita K; Pentheroudakis G; Tabernero J; Zielinski C; Wollins DS; Schilsky RL J Clin Oncol; 2019 Feb; 37(4):336-349. PubMed ID: 30707056 [TBL] [Abstract][Full Text] [Related]
20. Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring. Gyawali B; de Vries EGE; Dafni U; Amaral T; Barriuso J; Bogaerts J; Calles A; Curigliano G; Gomez-Roca C; Kiesewetter B; Oosting S; Passaro A; Pentheroudakis G; Piccart M; Roitberg F; Tabernero J; Tarazona N; Trapani D; Wester R; Zarkavelis G; Zielinski C; Zygoura P; Cherny NI ESMO Open; 2021 Jun; 6(3):100117. PubMed ID: 33887690 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]